SPUTOLYSIN

Main information

  • Trade name:
  • SPUTOLYSIN MUCOLYTIC POWDER FOR HORSES
  • Pharmaceutical form:
  • ORAL POWDER, PRE-MIX
  • Units in package:
  • 420g
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • SPUTOLYSIN MUCOLYTIC POWDER FOR HORSES
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • HORSE | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH PERFORMANCE HORSES | HORSES AT STUD | MARE | PACER | POL
  • Therapeutic area:
  • mucolytic
  • Therapeutic indications:
  • COUGH SUPPRESSION | BRONCHITIS | BRONCHODILATION | COUGH SUPPRESSANTS | DECONGESTANTS | EXPECTORANTS | MUCOID SECRETIONS | MUCOLYTICS | RESPIRATORY CONDITIONS | SINUSITIS
  • Product summary:
  • An aid in the treatment of respiratory disease in horses.Bacterial infections should be treated with Sputolysin together with an appropriate antibiotic or antibacterial. Should not be mixed with injectable solutions other than antibiotics/anti-bacterials (TMPS).

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered and available
  • Authorization number:
  • 35961/0510
  • Authorization date:
  • 18-08-2010
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

420g

shou ld be ext ended to at

least 3 w eeks.

Concomitant

treat men t w ith an antib ac-

terial

is recom mended w hen bacteria l i n-

fection i s present. Sputo lysin" is c

patible

with

ibioti

c prepa rations

presently available. It

shou ld

be mix ed

other

in jectable solutions.

TWIT

HHO LDING PERIO D (HO

RSES

DO NOT USE less t han 28 days befor e

laughter

f or

human

co nsu

i on.

First Aid

poi soning occurs , contact a do ctor or

Poisons

Information

Cent re.

Phone Austra lia 131126

Disposa l

Dispose

emp ty conta in er by wrappi ng

wi t h paper and p

utting

in garbage.

Boehringer I ngelh eim

Limit ed

Anima

Healt h Div is

Leve

78 Wa

terloo

Road

North

Ryde NSW 2113

Australia

Boe

h

ringer

Ingelheim

i ng infecti on of pneumonia . Sputolysin"

has been shown to have a cough-sup-

pressant

effe ct

comparable to t hat of

codeine.

Sputolysin " has been administered con -

currently w it h a range

antibiot

ics and

anti-bacteria ls (TMPS).

Directions

Twice daily adm

inistrat

ion of

0.3 mg ac-

e i ngredie nt per kg bodywe ight .

Adu lt

horses (500 kg):

30 g powder twice daily in t he food.

Small

horses , pon ies and foals:

g powder per 170 kg bodyweight twice

daily .

The measure holds 5 g.

Sputolysin" powder should be given for

12-14

days. In chronic cases treat ment

CAUTION

KEEP

OUTOF

REAC

H OFC

HILDREN

FOR

ANIMAL

TREAT

MENT

ONLY

Sputol

ys

i

Mucolytic

Powder

f o r Horses

ACTIVE CONSTITUENT PERg:

dembrexine

hydrochlorid

monohydrate

5 mg

J3107

U000073

Note: The

following

changes w ill

during

Sputolysin" therapy:

Increased nasal

discharge .

Change from dry to

moist

cough together

with

a reduct ion i n coughing.

Properties

Sputolysin " increases secret

of the ser-

ous cells in the glands of the nasal, tracheal

and bronchial

cells and in type II

alveolar

cells .

Surfactant stabilises

alevoli

protects the

respir ato ry epith

elium

from

the adhesion

vi rul ent

bact eria and

support

s pha gocyto-

sis. Sputolysin" compensates for any reduc-

tion

pulmonary

surfac

tant

(reduction of

surface tens

i n the alveolar region )

dur-

ing stress,

hun ger, transport , cold or

dur-

Batch No.:

Expiry Date:

Storage

Store below 25° C (Air Cond

itionin

APVMA No.

35961/420

10510

60006313IAU13

Indica

tions

To aid in the treatment

respiratory dis-

ease in horses. All

respiratory i nf ecti ons

wi th

incr

eased secretions. Acute , sub-acute

bronch it is. Chron ic respi ratory disease. I n-

fection of the uppe r airways.

Bacterial

i nfecti on should be treated

with

appropriate

antibiotic

antibact

erial.

Foal

pneu

ia: Sputolysin" to gether wi t h

th e appropria te a

ntibiotic

or ant

ibact

erial

i ndicated.

Sputol ysin " i ncreases

pulmonary

surfact ant

(AAF)which is decreased

during

infe

cti o n.

Date:

10.06.2010

Material number:

600063 13/ AU/3

Product:

Sputolysin

Country:

Australia

Dimensions:

80x8

5 mm

Scale:

1 : 1

Number of colours:

420 g

7.74pt Point

Black

Colour

codes:

Pantone

1375

ntone

356 C

m Vetmedica GmbH

RLP

APPROVED

Info

pest

Verified

10-1-2019


Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment

Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment

Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment of maple syrup urine disease, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-12-2018

EU/3/10/760 (TESARO Bio Netherlands B.V.)

EU/3/10/760 (TESARO Bio Netherlands B.V.)

EU/3/10/760 (Active substance: (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt) - Transfer of orphan designation - Commission Decision (2018)8636 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002385

Europe -DG Health and Food Safety

27-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Potassium citrate monohydrated,potassium hydrogen carbonate (ADV7103), decision type: , therapeutic area: , PIP number: P/0214/2018

Opinion/decision on a Paediatric investigation plan (PIP): Potassium citrate monohydrated,potassium hydrogen carbonate (ADV7103), decision type: , therapeutic area: , PIP number: P/0214/2018

Opinion/decision on a Paediatric investigation plan (PIP): Potassium citrate monohydrated,potassium hydrogen carbonate (ADV7103), decision type: , therapeutic area: , PIP number: P/0214/2018

Europe - EMA - European Medicines Agency

22-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Exviera,Dasabuvir (sodium monohydrate), decision type: , therapeutic area: , PIP number: P/0174/2018

Opinion/decision on a Paediatric investigation plan (PIP): Exviera,Dasabuvir (sodium monohydrate), decision type: , therapeutic area: , PIP number: P/0174/2018

Opinion/decision on a Paediatric investigation plan (PIP): Exviera,Dasabuvir (sodium monohydrate), decision type: , therapeutic area: , PIP number: P/0174/2018

Europe - EMA - European Medicines Agency

21-11-2018

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Active substance: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride) - Orphan designation - Commission Decision (2018)7791 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/040/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Active substance: Glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine) - Orphan designation - Commission Decision (2018)7277 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/18

Europe -DG Health and Food Safety

27-7-2018

EU/3/16/1635 (Leadiant GmbH)

EU/3/16/1635 (Leadiant GmbH)

EU/3/16/1635 (Active substance: N-acetyl-D-mannosamine monohydrate) - Transfer of orphan designation - Commission Decision (2018)5053 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/228/15/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3809 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/092/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3808 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/084/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/794 (Celgene Europe B.V.)

EU/3/10/794 (Celgene Europe B.V.)

EU/3/10/794 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3803 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/069/10/T/03

Europe -DG Health and Food Safety